Join us to learn more about Alexion Pharmaceuticals, a global leader in the biopharmaceutical industry based in Connecticut, and a joint Innovation Fund pilot program launching this fall. Alexion was established in 1992 and is headquartered in New Haven. The Company’s mission is to develop and deliver life-transforming therapies for patients with devastating and rare diseases who often have no effective treatment options. Alexion developed and commercialized Soliris® (eculizumab), the world’s first approved terminal complement inhibitor, and also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa). Members of Alexion’s leadership and R&D teams will be coming to Storrs on December 2nd to present information about Alexion’s current research interests to UConn and UConn Health faculty. Detailed information will also be provided about the new joint Innovation Fund pilot program launching this fall at UConn and UConn Health. After the presentations, there will be time for faculty to speak directly with the Alexion team. Lunch will be served. Registration recommended. Open to all from the UConn and UConn Health research community. Register at http://www.ovpr.eventbrite.com